Medigen Vaccine Biologics Corporation (TPEX:6547)

Market Cap	20.84B +63.2%
Revenue (ttm)	573.85M -9.2%
Net Income	-166.77M
EPS	-0.51
Shares Out	328.75M
PE Ratio	n/a
Forward PE	68.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	110,000
Open	63.30
Previous Close	63.40
Day's Range	62.50 - 64.40
52-Week Range	33.50 - 67.90
Beta	0.00
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respirat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 103
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6547

Financial Performance

In 2025, Medigen Vaccine Biologics's revenue was 613.17 million, an increase of 1.24% compared to the previous year's 605.64 million. Losses were -281.71 million, 250.1% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 8, 2026

Data Sources Report a data error